Could low-dose naltrexone be an effective treatment for Hailey-Hailey Disease?

Main Article Content

Denisse Izquierdo Benoit Renvoise Kathleen LaPoint Arvin M. Gouw Jimmy C.-H. Lin Imran Babar



Article Details

How to Cite
IZQUIERDO, Denisse et al. Could low-dose naltrexone be an effective treatment for Hailey-Hailey Disease?. Molecular Medicine Letters, [S.l.], v. 1, n. 1, aug. 2016. Available at: <>. Date accessed: 19 aug. 2017.


1. Missiaen, L., Dode, L., Vanoevelen, J., Raeymaekers, L. & Wuytack, F. Calcium in the Golgi apparatus. Cell Calcium 41, 405–16 (2007).

2. Burge, S. M. Hailey-Hailey disease: the clinical features, response to treatment and prognosis. Br J Dermatol 126, 275–282 (1992).

3. Chiaravalloti, A. & Payette, M. Hailey-hailey disease and review of management. J Drugs Dermatol 13, 1254–1257 (2014).

4. Brown, N. & Panksepp, J. Low-dose naltrexone for disease prevention and quality of life. Med. Hypotheses 72, 333–7 (2009).

5. Meng, J. et al. Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs). Int Immunopharmacol 17, 1084–1089 (2013).

6. Younger, J., Noor, N., McCue, R. & Mackey, S. Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 65, 529–538 (2013).

7. Younger, J., Parkitny, L. & McLain, D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin. Rheumatol. 33, 451–459 (2014).

8. Ngian, G.-S., Guymer, E. K. & Littlejohn, G. O. The use of opioids in fibromyalgia. Int. J. Rheum. Dis. 14, 6–11 (2011).

9. Cree, B. A. C., Kornyeyeva, E. & Goodin, D. S. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann. Neurol. 68, 145–150 (2010).

10. Gironi, M. et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult. Scler. 14 , 1076–1083 (2008).

11. Zagon, I. S., Rahn, K. A., Turel, A. P. & McLaughlin, P. J. Endogenous Opioids Regulate Expression of Experimental Autoimmune Encephalomyelitis: A New Paradigm for the Treatment of Multiple Sclerosis. Exp. Biol. Med. 234 , 1383–1392 (2009).

12. Di Paola, A. et al. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp. Clin. Trials 39, 256–68 (2014).

13. Bihari, B. Efficacy of low dose naltrexone as an immune stabilizing agent for the treatment of HIV/AIDS. AIDS Patient Care 9, 3 (1995).

14. Segal, D., MacDonald, J. K. & Chande, N. Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. (2014).

15. Khan, A. Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3--a case report. Oral Health Dent. Manag. 13, 721–4 (2014).

16. NGIAN, G.-S., GUYMER, E. K. & LITTLEJOHN, G. O. The use of opioids in fibromyalgia. Int. J. Rheum. Dis. 14, 6–11 (2011).

17. Wolfhagen, F. H. et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 113, 1264–9 (1997).

18. Terg, R., Coronel, E., Sordá, J., Muñoz, A. E. & Findor, J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J. Hepatol. 37, 717–22 (2002).

19. Mansour-Ghanaei, F. et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J. Gastroenterol. 12, 1125–8 (2006).

20. Heyer, G., Groene, D. & Martus, P. Efficacy of naltrexone on acetylcholine-induced alloknesis in atopic eczema. Exp. Dermatol. 11, 448–55 (2002).

21. Malekzad, F. et al. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. J. Eur. Acad. Dermatol. Venereol. 23, 948–50 (2009).

22. Weisshaar, E. et al. European guideline on chronic pruritus. Acta Derm. Venereol. 92, 563–81 (2012).

23. Hailey-Hailey Disease Worldwide Support Group.

24. Bigliardi, P. L., Neumann, C., Teo, Y. L., Pant, A. & Bigliardi-Qi, M. Activation of the δ-opioid receptor promotes cutaneous wound healing by affecting keratinocyte intercellular adhesion and migration. Br. J. Pharmacol. 172, 501–514 (2015).